Pfizer plans to charge $110 to $130 per dose for its COVID-19 vaccine once government purchases end next year, the drugmaker's U.S. president said on an investor call Thursday.
The big picture: Weak demand for the shots and private market pressures were expected to cost manufacturers billions once government purchases end. Price increases, while expected, could lead to higher insurance premiums.